Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

The en­zyme en­gi­neer­ing spe­cial­ists at Codex­is are giv­ing up on mak­ing their own ther­a­pies, in­stead fo­cus­ing on sell­ing its tech­nolo­gies and ser­vices to cus­tomers — in­clud­ing process­es to sup­port com­mer­cial-scale man­u­fac­tur­ing of RNAi drugs.

As a re­sult, the com­pa­ny said it will let 25% of its staff go while con­sol­i­dat­ing its San Car­los, CA fa­cil­i­ty to its Red­wood City, CA head­quar­ters. It had 248 em­ploy­ees, both full-time and part-time, at the end of 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER